A Study of RO4917523 in Patients With Fragile X Syndrome

ClinicalTrials.gov ID: NCT01517698

Public ClinicalTrials.gov record NCT01517698. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This multi-center, randomized, double-blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of RO4917523 in adolescent and adult patients with fragile X syndrome. Patients will be randomized to receive oral doses of 0.5 mg or 1.5 mg of RO4917523, or matching placebo once daily. The anticipated time on study treatment is 12 weeks.

Study identification

NCT ID: NCT01517698
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 185 participants

Conditions and interventions

Conditions

Fragile X Syndrome

Interventions

Drug

Eligibility (public fields only)

Age range: 14 Years to 50 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2012 (Type not available)
Primary completion: Apr 2014 (Actual)
Completion: Apr 2014 (Actual)
Last update posted: Jul 11, 2016

2012 – 2014

United States locations

U.S. sites: 20
U.S. states: 17
U.S. cities: 20

Facility	City	State	ZIP	Site status
Not listed	Phoenix	Arizona	85006	—
Not listed	Long Beach	California	90806	—
Not listed	Sacramento	California	95817	—
Not listed	Aurora	Colorado	80045	—
Not listed	Washington D.C.	District of Columbia	20010	—
Not listed	Decatur	Georgia	30033	—
Not listed	Chicago	Illinois	60612	—
Not listed	Iowa City	Iowa	52242-1083	—
Not listed	Louisville	Kentucky	40202	—
Not listed	Baltimore	Maryland	21205	—
Not listed	Worcester	Massachusetts	01655	—
Not listed	New York	New York	10029	—
Not listed	Staten Island	New York	10314	—
Not listed	Durham	North Carolina	27710	—
Not listed	Cincinnati	Ohio	45229	—
Not listed	Media	Pennsylvania	19063	—
Not listed	Nashville	Tennessee	37203	—
Not listed	Houston	Texas	77030	—
Not listed	San Antonio	Texas	78258	—
Not listed	Seattle	Washington	98145	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01517698, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 11, 2016 · Synced Oct 20, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01517698 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →